LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Human natural regulatory CD4(+) T cells comprise 5-10% of peripheral CD4(+)T cells. They constitutively express the IL-2Ralpha-chain (CD25) and the nuclear transcription Foxp3. These cells are heterogeneous and contain discrete subsets with distinct phenotypes and functions. Studies in mice report that LAG-3 has a complex role in T cell homeostasis and is expressed in CD4(+)CD25(+) T regulatory cells. In this study, we explored the expression of LAG-3 in human CD4(+) T cells and found that LAG-3 identifies a discrete subset of CD4(+)CD25(high)Foxp3(+) T cells. This CD4(+)CD25(high)Foxp3(+)LAG-3(+) population is preferentially expanded in the PBMCs of patients with cancer, in lymphocytes of tumor-invaded lymph nodes and in lymphocytes infiltrating visceral metastasis. Ex vivo analysis showed that CD4(+)CD25(high)Foxp3(+)LAG-3(+) T cells are functionally active cells that release the immunosuppressive cytokines IL-10 and TGF-beta1, but not IL-2. An in vitro suppression assay using CD4(+)CD25(high)LAG-3(+) T cells sorted from in vitro expanded CD4(+)CD25(high) regulatory T cells showed that this subset of cells is endowed with potent suppressor activity that requires cell-to-cell contact. Our data show that LAG-3 defines an active CD4(+)CD25(high)Foxp3(+) regulatory T cell subset whose frequency is enhanced in the PBMCs of patients with cancer and is expanded at tumor sites.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, LAG3 can positively induce Treg cell activation and stimulate its immunosuppressive function [325, 326].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [326]
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Moreover, although data remain controversial and depend on the type of tumor studied (21), a higher accumulation of Treg cells is often associated with advanced disease stages and is inversely correlated with favorable prognosis and overall survival (22, 23).”
BackgroundCD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · cited 1×
“This same set of markers, together with a low expression level of CD127 (6, 7), also identifies human natural Treg cells.”
BackgroundMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
CD4+CD25high Regulatory Cells in Human Peripheral Blood
Baecher-Allan, C., Brown, J. A., Freeman, G. J., & Hafler, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1245 · Cited by 1,859
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512 · cited 1×
“This same set of markers, together with a low expression level of CD127 (6, 7), also identifies human natural Treg cells.”
BackgroundICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J., & Enk, A. H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1285 · Cited by 1,255 · cited 1×
“Natural Treg cells, upon TCR engagement (15, 16), exert their immunosuppressive functions in a contact-dependent fashion.”
BackgroundInterleukin‐10‐secreting type 1 regulatory T cells in rodents and humans
Grazia Roncarolo, M., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., & Levings, M. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00420.x · Cited by 1,173 · cited 1×
“Two subsets of induced Treg cells have been described and are shown to also exist in humans: Tr1 cells, which secrete high levels of IL-10 and arise from CD4 T cells upon encountering Ags in a tolerogenic environment (1), and Th3 cells, which are induced by oral Ag administration and secrete high levels of TGF-b1 (2).”
Background
Cited by
Items 101–200 of 350
Sun, L., Jin, H., & Li, H. (2016) · Oncotarget · doi:10.18632/oncotarget.8753 · Cited by 79
“However, OX40 and 4-1BB also inhibit the development and suppressive activity of Tregs [21, 49, 50] 4-1BB LAG-3 LAG-3 defines an active Tregs subset and contributes to their function.”
BackgroundInfluentialRegulation of regulatory T cells in cancer
Stockis, J., Roychoudhuri, R., & Halim, T. Y. F. (2019) · Immunology · doi:10.1111/imm.13064 · Cited by 68
Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
Lu, C., & Tan, Y. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200773 · Cited by 90
“29 In addition, LAG3-de fi cient Tregs exhibit enhanced Treg proliferation and function, which leads to the mitigation of autoimmune diseases.”
BackgroundSeven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity
Burnell, S. E. A., Capitani, L., MacLachlan, B. J., Mason, G. H., Gallimore, A., & Godkin, A. J. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab025 · Cited by 67
Hargadon, K. M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.37 · Cited by 67
Mechanism of T cell exhaustion in a chronic environment
Jin, H.-T., Jeong, Y. H., Park, H.-J., & Ha, S. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.4.217 · Cited by 72
“In melanoma patients, LAG-3 on Tregs was reported to mediate the reduction of CD8 T cell proliferation as well as the production of the immunosuppressive cytokines such as IL-10 and TGF-β1 (148).”
BackgroundGhosh, S., Sharma, G., Travers, J., Kumar, S., Choi, J., Jun, H. T., Kehry, M., Ramaswamy, S., & Jenkins, D. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0836 · Cited by 61
Progress of immune checkpoint LAG‑3 in immunotherapy (Review)
Shan, C., Li, X., & Zhang, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.12070 · Cited by 59
Variation of Tumor-Infiltrating Lymphocytes in Human Cancers: Controversy on Clinical Significance
Sasada, T., & Suekane, S. (2011) · Immunotherapy · doi:10.2217/imt.11.106 · Cited by 61
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
Fröhlich, A., Sirokay, J. D., Fietz, S., Vogt, T. J., Dietrich, J., Zarbl, R., Florin, M., Kuster, P., Saavedra, G., Valladolid, S. R., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102962 · Cited by 63
“High levels of LAG3 have been found on immunosuppressive Tregs in cancer patients [7], e.g. in melanoma and colorectal carcinoma [8].”
BackgroundInfluentialCD74 supports accumulation and function of regulatory T cells in tumors
Bonnin, E., Riestra, M. R., Marziali, F., Osuna, R. M., Denizeau, J., Maurin, M., Sáez, J. J., Jouve, M. J., Bonté, P., Richer, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47981-3 · Cited by 69
The Regulation of CD4+ T Cell Responses during Protozoan Infections
Engwerda, C. R., Ng, S. S., & Bunn, P. T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00498 · Cited by 62
“Several other molecules known to be involved in promoting T cell exhaustion, such as Tim-3 and Lag3, have also been linked with IL-10 expression (73, 74), but their precise relationships are not known.”
BackgroundLAG3 (CD223) and autoimmunity: Emerging evidence
Hu, S., Liu, X., Li, T., Li, Z., & Hu, F. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102504 · Cited by 58
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
Pesce, S., Trabanelli, S., Vito, C. D., Greppi, M., Obino, V., Guolo, F., Minetto, P., Bozzo, M., Calvi, M., Zaghi, E., et al. (2020) · Cancers · doi:10.3390/cancers12123504 · Cited by 57
Immune checkpoints and cancer development: Therapeutic implications and future directions
Mehdizadeh, S., Bayatipoor, H., Pashangzadeh, S., Jafarpour, R., Shojaei, Z., & Motallebnezhad, M. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153485 · Cited by 56
Common Features of Regulatory T Cell Specialization During Th1 Responses
Lambert, K., Moresi, C., Rakebrandt, N., Zhou, X., Schorer, M., Dolowschiak, T., Kirchner, F., Rost, F., Keller, C. W., McHugh, D., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01344 · Cited by 59
“In line with previous reports (35, 42), expression levels for Tim-3 and LAG-3 in the blood were very low and we could not observe an induction after influenza vaccination.”
ResultSlevin, S. M., Garner, L. C., Lahiff, C. J., Tan, M. T. K., Wang, L. M., Ferry, H., Greenaway, B., Lynch, K. D., Geremia, A., Hughes, S. A., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa054 · Cited by 55
Davidsson, S., Andrén, O., Ohlson, A., Carlsson, J., Andersson, S., Giunchi, F., Rider, J. R., & Fiorentino, M. (2017) · The Prostate · doi:10.1002/pros.23442 · Cited by 51
Emerging immune checkpoints for cancer therapy
Li, X., Hu, W., Zheng, X., Zhang, C., Du, P., Zheng, Z., Yang, Y., Wu, J., Ji, M. Q., Jiang, J., et al. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1071918 · Cited by 56
“And several subsets of LAg-3-expressing T cells are expanded in the peripheral blood of patients with advanced cancer [24,38,44].”
BackgroundEsparvarinha, M., Madadi, S., Aslanian‐Kalkhoran, L., Nickho, H., Dolati, S., Pia, H., Danaii, S., Taghavi, S., & Yousefi, M. (2022) · Cell Biology International · doi:10.1002/cbin.11955 · Cited by 53
“U.S. Food and Drug Administration (FDA) has been categorized anti‐ PD‐1 mediators such as pembrolizumab and nivolumab as pregnancy category D, while anti‐CTLA‐4 antibody ipilimumab is categorized as pregnancy category C (Campos et al., 2020, Stenger).”
BackgroundGuo, Z., Wen, Z., Qin, A., Zhou, Y., Liao, Z., Liu, Z., Liang, Y., Ren, T., & Xu, L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203233 · Cited by 52
“Previous reports showed that the expansion of Tregs was critical for their accumulation in various settings (32, 34).”
BackgroundExpression of CD39 on FoxP3+ T regulatory cells correlates with progression of HBV infection
Tang, Y., Li, J., Zheng, Y., Ni, B., & Wu, Y. (2012) · BMC Immunology · doi:10.1186/1471-2172-13-17 · Cited by 49
“through distinct mechanisms, including specific profiles of immunomodulatory factors, such as IL-10, TGF-b, granzyme B, perforin, CTLA-4, GITR, and Lag-3 [10-12].”
BackgroundInfluentialDefining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function
Gootjes, C., Zwaginga, J. J., Roep, B. O., & Nikolić, T. (2024) · Cells · doi:10.3390/cells13110941 · Cited by 53
Beyond Type 1 Regulatory T Cells: Co-expression of LAG3 and CD49b in IL-10-Producing T Cell Lineages
Huang, W., Solouki, S., Carter, C., Zheng, S. G., & August, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02625 · Cited by 54
Kim, D., Kim, G., Yu, R., Lee, J., Kim, S., Gleason, M. R., Qiu, K., Montauti, E. I., Wang, L. L., Fang, D., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.008 · Cited by 57
Therapeutic strategies for gastric cancer targeting immune cells: Future directions
Zhao, Y. F., Bai, Y., Shen, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992762 · Cited by 57
Challenges and future perspectives of T cell immunotherapy in cancer
de Aquino, M. T. P., Malhotra, A., Mishra, M. K., & Shanker, A. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.05.018 · Cited by 48
Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
Liu, Q., Qi, Y., Zhai, J., Kong, X., Wang, X., Wang, Z., Fang, Y., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.599207 · Cited by 56
Gertel, S., Polachek, A., Elkayam, O., & Furer, V. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103085 · Cited by 51
Juno, J. A., Stalker, A. T., Waruk, J. L., Oyugi, J., Kimani, M., Plummer, F. A., Kimani, J., & Fowke, K. R. (2015) · Retrovirology · doi:10.1186/s12977-015-0142-z · Cited by 44
“The Creative Commons Public Domain g/publicdomain/zero/1.0/) applies to the data made available in this article, expression is negligible, but it is known to be expressed on activated T and NK cells [5,10], Tregs [11,12], iNKT cells [13] and some pDC populations [14].”
BackgroundInfluentialThe Regulatory-T-Cell Memory Phenotype: What We Know
Khantakova, J. N., Сергеевич, Б. А., & Sennikov, S. V. (2022) · Cells · doi:10.3390/cells11101687 · Cited by 49
Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
Zhai, Y., Moosavi, R., & Chen, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645699 · Cited by 49
“When CTLA-4 on Tregs binds with CD80 and CD86 on DCs, the DCs show reduced antigen-presenting capacity (46).”
BackgroundInfluentialKhosroshahi, L. M., Parhizkar, F., Kachalaki, S., Aghebati‐Maleki, A., & Maleki, L. A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107935 · Cited by 46
Kaptein, P., Slingerland, N., Metoikidou, C., Prinz, F., Brokamp, S., Machuca-Ostos, M., de Roo, G., Schumacher, T. N., Yeung, Y. A., Moynihan, K. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1263 · Cited by 44
“However, the clinical value of systemic IL2 administration is limited by toxicity and immunosuppressive effects following Treg activation (64–66).”
Regulatory T cells and potential inmmunotherapeutic targets in lung cancer
Zhang, D., Chen, Z., Wang, D. C., & Wang, X. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9566-0 · Cited by 43
Xie, Q., Liu, X., Liu, R., Pan, J., & Liang, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02166-w · Cited by 49
“It was reported that LAG-3 + FoxP3 + Treg was expanded in tumors from CRC patients [45], and IL-10 and TGF-β-producing Treg leads to poor prognosis of CRC patients [46].”
Do, J., Zwick, D. B., Kenyon, J. D., Zhong, F., Askew, D., Huang, A. Y.-C., Hof, W. V., Finney, M. R., & Laughlin, M. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-90115-8 · Cited by 43
Immunomodulatory effect of locoregional therapy in the tumor microenvironment
Xie, L., & Meng, Z. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.017 · Cited by 42
Fantini, M. C., Favale, A., Onali, S., & Facciotti, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186744 · Cited by 40
“FoxP3+LAG-3+ isolated from these patients showed higher secretion of IL-10 and TGF 1 and suppressive activity than LAG-3-Tregs [70].”
BackgroundMalignant melanoma—The cradle of anti-neoplastic immunotherapy
Koller, K. M., Wang, W., Schell, T. D., Cozza, E. M., Kokolus, K. M., Neves, R. I., Mackley, H. B., Pameijer, C. R., Leung, A. M., Anderson, B. E., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.010 · Cited by 43
“vivo analysis showed that this subpopulation of cells released immunosuppressive cytokines IL-10 and TGF-1, but not IL-2 [329] .”
BackgroundRoles, function and relevance of LAG3 in HIV infection
Graydon, C. G., Balasko, A. L., & Fowke, K. R. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007429 · Cited by 45
Intrahepatic TH17/TReg Cells in Homeostasis and Disease—It’s All About the Balance
Drescher, H. K., Bartsch, L. M., Weiskirchen, S., & Weiskirchen, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.588436 · Cited by 47
Wardell, C. M., MacDonald, K. N., Levings, M. K., & Cook, L. E. (2020) · European Journal of Immunology · doi:10.1002/eji.202048746 · Cited by 40
Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics
Dwivedi, M., Tiwari, S., Kemp, E. H., & Begum, R. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10450 · Cited by 42
Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands
Kamali, A. N., Bautista, J. M., Eisenhut, M., & Hamedifar, H. (2023) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355231192043 · Cited by 53
Camisaschi, C., Filipazzi, P., Tazzari, M., Casati, C., Beretta, V., Pilla, L., Patuzzo, R., Maurichi, A., Cova, A., Maio, M., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1397-7 · Cited by 42
“Immunomonitoring was performed using an ex vivo IFN-c ELISpot assay (1-D1K, Mabtech AB, Nacka, Sweden) after thawed PBMCs were incubated overnight at 37 C in culture medium as previously described [23].”
Methodvan Herk, E. H., & Velde, A. A. T. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13342 · Cited by 39
Recent Advances in the Biology, Therapy and Management of Melanoma
Davids, L. M. (2013) · InTech eBooks · doi:10.5772/46052 · Cited by 38
Toker, A., & Ohashi, P. S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.05.001 · Cited by 41
Kamal, A. M., Wasfey, E. F., Elghamry, W. R., Sabry, O. M., Elghobary, H., & Radwan, S. M. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.06.007 · Cited by 41
Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer
Camisaschi, C., Vallacchi, V., Vergani, E., Tazzari, M., Ferro, S., Tuccitto, A., Kuchuk, O., Shahaj, E., Sulsenti, R., Castelli, C., et al. (2016) · Vaccines · doi:10.3390/vaccines4040038 · Cited by 36
“characterized by the expression of LAG-3 [63].”
Translation of cancer immunotherapy from the bench to the bedside
Guo, Q., Huang, F., Gonçalves, C., Rincon, S. V. D., & Miller, W. H. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.001 · Cited by 43
Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis
Lavon, I., Heli, C., Brill, L., Charbit, H., & Vaknin‐Dembinsky, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00835 · Cited by 41
LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy
Friedman, L. A., Ring, K. L., & Mills, A. M. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000608 · Cited by 37
“LAG-3 expression is thought to play a role in evasion of the host immune response in ovarian (12), renal (13), and colorectal cancers (3,14), as well as in melanoma (14).”
BackgroundEllis, J., Marks, D. J., Srinivasan, N., Barrett, C., Hopkins, T. G., Richards, A., Fuhr, R., Albayaty, M., Coenen, M., Liefaard, L., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2091 · Cited by 39
Poirier, N., Haudebourg, T., Brignone, C., Dilek, N., Hervouet, J., Minault, D., Coulon, F., de Silly, R. V., Triebel, F., Blancho, G., et al. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04329.x · Cited by 37
Regulatory issues in immunity to liver and blood-stage malaria
Budimir, N., Kurup, S. P., & Harty, J. T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.06.008 · Cited by 39
“In addition to CTLA-4 [59], various other inhibitory receptors like PD-1 [60] and LAG3 [61] are also associated with Treg cells.”
BackgroundMcAllister, M. J., Underwood, M. A., Leung, H. Y., & Edwards, J. (2018) · Translational research · doi:10.1016/j.trsl.2018.11.004 · Cited by 36
“This subpopulation of LAG-3 expressing Tregs display a terminal-effector phenotype with expression identified in peripheral blood of CaP patients (110).”
BackgroundVolk, V., Theobald, S. J., Danisch, S., Khailaie, S., Kalbarczyk, M., Schneider, A., Bialek-Waldmann, J. K., Krönke, N., Deng, Y., Eiz‐Vesper, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.614876 · Cited by 34
“LAG-3 is another checkpoint receptor that defines a potent regulatory T cell subset that occurs more frequently in cancer patients and is expanded at tumor sites (38).”
BackgroundBeyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity
Nirmala, S. S., Kayani, K., Gliwiński, M., Hu, Y., Iwaszkiewicz‐Grześ, D., Piotrowska, M., Sakowska, J., Tomaszewicz, M., Morales, J. M. M., Lakshmi, K., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1321228 · Cited by 45
Qi, Y., Chen, L., Liu, Q., Kong, X., Fang, Y., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563258 · Cited by 44
“LAG3 is widely expressed on the membranes of various immune cells, including T cells (CD4+/CD8+ T cells), regulatory T cells, B cells, and natural killer cells (31).”
BackgroundPhenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer
Chaudhary, B., Samid, M. A. A., al-Ramadi, B. K., & Elkord, E. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.900539 · Cited by 35
“LAG-3 (CD233) (co-expressed with CD49b) In tumour-invaded LN, PB, TT of MM & CRC patients and TILs in Hodgkin’s lymphoma Late activation marker also expressed by NK cells and B cells [89,102]”
BackgroundDavern, M., Donlon, N. E., O’Connell, F., Gaughan, C., O’Donovan, C., McGrath, J., Sheppard, A. D., Hayes, C., King, R., Temperley, H. C., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04440-0 · Cited by 35
Regulatory T‐cells promote hepatitis B virus infection and hepatocellular carcinoma progression
Li, W., Han, J., & Wu, H. M. (2016) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2016.09.001 · Cited by 37
Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 35
Liu, Y., Zhang, Z., Wang, S., Fu, S., Cheng, X., Chen, R., & Sun, T. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108900 · Cited by 35
Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
Yu, L., Sun, M., Zhang, Q., Zhou, Q., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982026 · Cited by 33
“Lag-3 is also a biomarker for active CD4CD25Foxp3 Tregs (78).”
BackgroundCo-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?
Liu, W., Almo, S. C., & Zang, X. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1186690 · Cited by 34
“LAG-3 defines a population of active CD4+CD25+Foxp3+ Tregs, which is expanded at tumor sites in cancer patients (Camisaschi et al., 2010).”
BackgroundRegulatory T Cells in the Tumor Microenvironment
Dadey, R., Workman, C. J., & Vignali, D. A. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_6 · Cited by 34
Zhdanov, D. D., Gladilina, Y. A., Pokrovsky, V. S., Grishin, D. V., Grachev, V. A., Orlova, V. S., Pokrovskaya, M. V., Alexandrova, S. S., & Sokolov, N. N. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.06.008 · Cited by 28
Arolt, C., Meyer, M. F., Rüsseler, V., Nachtsheim, L., Wuerdemann, N., Dreyer, T., Gattenlöhner, S., Wittekindt, C., Buettner, R., Quaas, A., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02551-6 · Cited by 31
Al-Badran, S. S. F., Grant, L., Campo, M. V., Inthagard, J., Pennel, K. A. F., Quinn, J. A., Konanahalli, P., Hayman, L., Horgan, P. G., McMillan, D., et al. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.193 · Cited by 31
Function and regulation of LAG3 on CD4+CD25- T cells in non-small cell lung cancer
Ma, Q., Huang, D., Zhang, H., Wang, S., & Chen, X. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.026 · Cited by 32
Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
Ho, R. L. Y., & Ho, I. A. W. (2021) · Cancers · doi:10.3390/cancers13153686 · Cited by 34
“Furthermore, LAG-3-expressing Treg produced elevated levels of TGF-β and IL-10, influencing the TME to be more immunosuppressive [136].”
BackgroundT regulatory cells in B‐cell malignancy – tumour support or kiss of death?
Lindqvist, C. A., & Loskog, A. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03539.x · Cited by 35
Konnai, S., Suzuki, S., Shirai, T., Ikebuchi, R., Okagawa, T., Sunden, Y., Mingala, C. N., Onuma, M., Murata, S., & Ohashi, K. (2012) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2012.09.005 · Cited by 37
Bao, Y., Jiang, A., Dong, K., Gan, X., Gong, W., Wu, Z., Liu, B., Bao, Y., Wang, J., & Wang, L. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.62553 · Cited by 35
“In addition, Lymphocyte activation gene 3 protein (LAG3/CD223) is a T cell inhibitory receptor which can transfer suppressive signals cooperatively with PDCD1/PD-1 [30].”
BackgroundTumor immunotherapy: Mechanisms and clinical applications
Nong, C., Guan, P., Li, L., Zhang, H., & Hu, H. (2022) · MedComm – Oncology · doi:10.1002/mog2.8 · Cited by 30
Convergences and Divergences of Thymus- and Peripherally Derived Regulatory T Cells in Cancer
Burocchi, A., Colombo, M. P., & Piconese, S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00247 · Cited by 27
“LAG-3 is upregulated in tumor-infiltrating Treg and experiments with anti-LAG-3 mAb demonstrated that functional LAG-3 is required for maximal Treg suppressive function (20, 21).”
Background[Mechanisms of suppression of regulatory T-cells (Treg)].
Flores, J. M. G., & Portales‐Pérez, D. P. (2013) · PubMed · Cited by 27
Zhdanov, D. D., Gladilina, Y. A., Grishin, D. V., Grachev, V. A., Orlova, V. S., Pokrovskaya, M. V., Alexandrova, S. S., Pokrovsky, V. S., & Sokolov, N. N. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.07.017 · Cited by 25
Armitage, J. D., Newnes, H. V., McDonnell, A. M., Bosco, A., & Waithman, J. C. (2021) · Cells · doi:10.3390/cells10010056 · Cited by 28
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
Franzese, O., Torino, F., Fuggetta, M. P., Aquino, A., Roselli, M., Bonmassar, E., Giuliani, A., & D’Atri, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16335 · Cited by 23
“A population of expanded CD4+CD25highFoxp3+ Tregs expressing LAG3 has been identified in the peripheral blood, in T cells of tumor-invaded lymph nodes and in T cells infiltrating the visceral metastasis of melanoma and sarcoma patients [162].”
BackgroundXia, J., Ni, Z., Wang, J., Zhu, S., & Ye, H. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3771 · Cited by 24
“Cells were incubated in culture media supplemented with 10% human AB serum (Sigma) and 100 U/mL IL-2 (Thermo Fisher).”
Novel Targets for the Treatment of Melanoma
Ambrosi, L., Khan, S. A., Carvajal, R. D., & Yang, J. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0849-4 · Cited by 24
Immunotherapeutic targets in non‐small cell lung cancer
Sadeghirad, H., Bahrami, T., Layeghi, S. M., Yousefi, H., Rezaei, M., Hosseini‐Fard, S. R., Radfar, P., Warkiani, M. E., O'Byrne, K. J., & Kulasinghe, A. (2022) · Immunology · doi:10.1111/imm.13562 · Cited by 27
Castelli, C., Triebel, F., Rivoltini, L., & Camisaschi, C. (2014) · OncoImmunology · doi:10.4161/21624011.2014.967146 · Cited by 23
“LAG-3 also defines Tregs with enhanced suppressive functions that accumulate in melanoma-invaded LNs where it functions as selective marker for human Treg type 1 cells.(7,8) With the aim of reverting exhaustion and possibly limiting Treg functions, clinical trials using anti-LAG-3 mAbs with or without anti-PD1 mAbs ar…”
BackgroundJin, H., Sun, L., Tang, L., Yu, W., & Li, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00138 · Cited by 25
The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer
Liu, C., Qifeng, J., & Shaolei, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01117-7 · Cited by 24
“As for the immune cell, autophagy induces abnormal protein degradation in tumor-specific CD8 + T cells and NK cells, allowing APCs to utilize these proteins as MHC-I and II [42].”
BackgroundUnraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy
Ryba-Stanisławowska, M. E. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00992-0 · Cited by 26
Xu, L., Xu, W., Wen, Z., & Xiong, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020282 · Cited by 28
Adoptive Cell Therapy for Lymphoma with CD4 T Cells Depleted of CD137-Expressing Regulatory T Cells
Goldstein, M. J., Kohrt, H. E. K., Houot, R., Varghese, B., Lin, J. T., Swanson, E., & Levy, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3375 · Cited by 23
“In human lymphoma-involved lymph nodes, CD137 identifies a population of activated Tregs Recent studies have identified cell surface markers that define a discrete subset of CD25FoxP3 Tregs preferentially expanded in patients with cancer (24).”
BackgroundChen, L., Huang, L., Gu, Y., Li, C., Sun, P., & Xiang, Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133883 · Cited by 24
Krzyżanowska, N., Wojas‐Krawczyk, K., Milanowski, J., & Krawczyk, P. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063087 · Cited by 20
Immunological and clinical implications of immune checkpoint blockade in human cancer
Kim, H., & Park, S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01140-1 · Cited by 22
Hübbe, M. L., Jæhger, D. E., Andresen, T. L., & Andersen, M. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.578349 · Cited by 20
“Lag-3+ Tregs produces high amounts of IL-10 and transforming growth factor beta (TGF-β) and expand in tumor tissue of patients with melanoma and colorectal cancer (30).”
BackgroundThe role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies
Sheida, F., Razi, S., Keshavarz‐Fathi, M., & Rezaei, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2011224 · Cited by 21
T cell subsets and colorectal cancer: Discerning the good from the bad
Scurr, M. J., Gallimore, A., & Godkin, A. J. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.08.004 · Cited by 20
Fat-1 transgenic cattle as a model to study the function of ω-3 fatty acids
Guo, T., Liu, X. F., Ding, X. B., Yang, F. F., Nie, Y., An, Y. J., & Guo, H. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-244 · Cited by 21
Rolig, A. S., Peng, X., Sturgill, E. R., Holay, N., Kasiewicz, M. J., Mick, C., McGee, G. H., Miller, W., Koguchi, Y., Kaufmann, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3702 · Cited by 22
Metadata
- Authors
- Camisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., Parmiani, G., Belli, F., Rivoltini, L., & Castelli, C.
- Affiliations
- Unit of Immunotherapy of Human Tumors
- Immutep S.A., Faculté de Pharmacie , Chatenay-Malabry,
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Corresponding author
- Camisaschi, Chiara
- Casati, Chiara
- Rini, Francesca
- Perego, Michela
- Parmiani, Giorgio
- Rivoltini, Licia
- Castelli, Chiara
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-06-01
- Volume
- 184
- Issue
- 11
- Pages
- 6545-6551
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2147968481
- Cited by
- 350
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 30 · 2023: 21 · 2022: 46 · 2021: 36 · 2020: 35 · 2019: 29 · 2018: 22 · 2017: 16 · 2016: 17 · 2015: 10 · 2014: 14 · 2013: 9 · 2012: 17
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- LAG-3, regulatory T cells, Foxp3, CD4+CD25high T cells, tumor-infiltrating lymphocytes, metastasis, immunosuppression, IL-10, TGF-β1, suppressor activity, cell-cell contact, tumor immunology, T cell subsets
- MeSH terms
- Lymphocyte Activation Gene 3 Protein, Cell Separation, Flow Cytometry, Humans, Lymphocyte Activation, Neoplasms, Antigens, CD, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory, Forkhead Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.